Reactome | Antagonism of Activin by Follistatin

Antagonism of Activin by Follistatin

Stable Identifier

R-HSA-2473224

Type

Pathway

Species

Homo sapiens

Compartment

extracellular region

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this pathway in the Pathway Browser

Both Follistatin (FST) and Follistatin-like-3 (FSTL3) irreversibly bind Activin dimers and prevent Activin from interacting with its receptor (reviewed in Schneyer et al. 2004, Xia and Schneyer 2009). Though functionally similar in vitro, FST and FSTL3 do not function identically in vivo. Mice lacking FST die shortly after birth due to defects in muscle and bone (Matzuk et al. 1995); mice lacking FSTL3 are viable but have altered glucose metabolism (Mukherjee et al. 2007).

Literature References

PubMed ID	Title	Journal	Year
17229845	FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults Mahan, A, Xia, Y, Thomas, MK, Rosen, ED, Schneyer, AL, Mukherjee, A, Raher, MJ, Sidis, Y, Bloch, KD	Proc. Natl. Acad. Sci. U.S.A.	2007
7885475	Multiple defects and perinatal death in mice deficient in follistatin Bradley, A, Roop, DR, Matzuk, MM, Vogel, H, Sellheyer, K, Lu, N	Nature	1995
19273500	The biology of activin: recent advances in structure, regulation and function Xia, Y, Schneyer, AL	J. Endocrinol.	2009
15451564	Differential actions of follistatin and follistatin-like 3 Xia, Y, Schneyer, A, Saito, S, Lin, HY, Sidis, Y, Keutmann, H, del Re, E	Mol. Cell. Endocrinol.	2004